New Reference: Ribociclib After Progression on CDK Inhibitros

2023-08-20

  • Study

    Phase II, double-blind, placebo-controlled trial (MAINTAIN)
    Patients with HR+, HER2- MBC, whose cancer progressed during ET and CDK4/6i
    ET+ Ribociclib (n=60) vs. ET (n=59)


  • Efficacy

    mPFS: 5.29 vs. 2.76 mos, HR:0.57, p=0.006
    12 mos PFS: 24.6 % vs. 7.4%


  • Safety

    Grade3: Neutropenia (40% vs.1.7%), AST increased (1.7% vs.6.8%).


    • Journal of Clin Oncol, JUL 2023

    Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

    http://doi.org/10.1200/JCO.22.02392

    Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023